The risk for major adverse cardiovascular events decreased with tirzepatide vs. liraglutide and semaglutide in patients with ...

Once-weekly tirzepatide conferred a similar cardiovascular risk as once-weekly dulaglutide in adults with type 2 diabetes and ...

A post hoc analysis of the SUMMIT trial, published in JACC, reveals that baseline body mass index (BMI) and fat distribution ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

This podcast was recorded on July 21, 2025. Tim Beyers: Is it time to buy biotech? You're listening to Motley Fool Money.

CINCINNATI — U.S. Customs and Border Protection (CBP) and the U.S. Food and Drug Administration (FDA) at the port of ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

If you’re struggling with weight, you’re not alone. Around 42 percent of American adults have obesity. In addition to ...

On the one hand, the company is struggling to stay competitive with its chief rival Eli Lilly, and on the other, compounders ...

Researchers introduced the PREVENT risk age equations to help determine risk of cardiovascular disease. (JAMA Cardiology) A ...

Summit Therapeutics Inc.'s valuation hinges on ivonescimab's potential, yet the data, competition, and regulatory issues ...